Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07738328

Terbinafine for CSA-AKI Prevention

Primary Objective: To evaluate the efficacy and safety of perioperative oral terbinafine in reducing the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI).Secondary Objectives:To assess the effects of terbinafine on the severity of post-cardiac surgery AKI, length of hospital stay, and 30-day major adverse kidney events (MAKE30);To evaluate its impacts on biomarkers of renal injury and inflammation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Acute Kidney Injury Cardiac Surgical Procedures Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Department of Kidney Transplantation, Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China

Location contact

Qiquan Sun

CONTACT

[email protected]

+86 13825109488

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged ≥18 and ≤75 years, without restriction on gender.
  • Patients with a definite clinical diagnosis scheduled for elective cardiac and macrovascular surgery with cardiopulmonary bypass (CPB) support, including but not limited to coronary artery bypass grafting (CABG), cardiac valve replacement/repair, structural heart disease surgery, aortic arch plasty, or combined procedures of the above surgeries.
  • Classified as high risk by AKI risk scoring system, with a total score ≥4 points.
  • The subject or their legal representative shall fully understand the purpose, procedures, potential risks and benefits of this study, and voluntarily sign the written informed consent form.

Exclusion criteria

  • Patients with severe chronic renal insufficiency (eGFR < 50 mL/min/1.73 m² or serum creatinine > 300 μmol/L), or those receiving any form of renal replacement therapy (e.g., hemodialysis, peritoneal dialysis).
  • Pre-existing acute kidney injury.
  • Presence of chronic or active liver diseases, including decompensated liver cirrhosis, active viral hepatitis, autoimmune liver disease, etc.; or preoperative laboratory tests showing ALT/AST ≥ 2 times the upper limit of normal (ULN).
  • Severe hematological diseases (preoperative white blood cell count < 3.0 × 10⁹/L, platelet count < 80 × 10⁹/L).
  • Uncontrolled active infections, or known immunodeficiency disorders (e.g., HIV infection, status post organ transplantation).
  • History of severe hypersensitivity to terbinafine or any excipients of its formulation.
  • Pregnant or lactating women, as well as women of childbearing potential who plan to conceive during the study and refuse to use effective contraception.
  • Participation in any other clinical trial of investigational drugs or medical devices within 3 months prior to screening.
  • Patients deemed inappropriate for enrollment in this study at the investigator's clinical discretion.

Treatment and study plan

Terbinafine

Drug

Terbinafine, an allylamine antifungal agent, is being repurposed for its potential antioxidant and anti-inflammatory properties to prevent acute kidney injury following cardiac surgery

Primary outcomes

  1. Incidence of CSA-AKI at 7 Days Post-Surgery

    Time frame: From day of surgery through postoperative day 7

    Defined according to KDIGO criteria: SCr increase ≥26.5 μmol/L within 48h, or SCr increase ≥1.5× baseline within 7d, or urine output <0.5 mL/kg/h for ≥6h.

Secondary outcomes

  1. Maximum KDIGO Stage of AKI Within 7 Days Post-Surgery

    Time frame: From day of surgery through postoperative day 7

    AKI severity is assessed by the maximum KDIGO stage within 7 days post-surgery, based on serum creatinine and urine output criteria. Stage 1: SCr increase ≥26.5 μmol/L within 48h, or increase to 1.5-1.9× baseline within 7d, or urine output <0.5 mL/kg/h for 6-12h; Stage 2: SCr increase to 2.0-2.9× baseline, or urine output <0.5 mL/kg/h for ≥12h; Stage 3: SCr increase to ≥3.0× baseline, or SCr ≥353.6 μmol/L, or initiation of RRT, or urine output <0.3 mL/kg/h for ≥24h, or anuria for ≥12h. The highest stage reached within the 7-day period is recorded.

  2. Use of Renal Replacement Therapy Within 30 Days Post-Surgery

    Time frame: Within 30 days post-surgery

    Documentation of whether the subject received any form of renal replacement therapy (including continuous renal replacement therapy, intermittent hemodialysis, peritoneal dialysis, etc.) within 30 days after surgery, based on clinical orders and treatment records. Binary outcome: yes/no.

  3. Duration of ICU stay and total hospital length of stay

    Time frame: Postoperative day of ICU discharge (varies, captured at the time of discharge) and postoperative day of hospital discharge (varies, captured at the time of discharge) - with data reported as cumulative days up to 30 days for ICU and up to 60 days for hos

    Data obtained from the hospital electronic medical record system or inpatient records. ICU stay is defined as the total number of days the subject spent in the ICU post-surgery (from ICU admission after surgery to ICU discharge). Total hospital length of stay is defined as the total number of days of hospitalization post-surgery (from the day of surgery to hospital discharge).

  4. Major adverse cardiovascular events within 30 days (MACE30)

    Time frame: Within 30 days post-surgery

    Data obtained from electronic medical records. MACE30 is defined as all-cause death, nonfatal myocardial infarction, or nonfatal stroke within 30 days post-surgery

  5. Major adverse kidney events within 30 days (MAKE30)

    Time frame: Within 30 days post-surgery

    Data obtained from electronic medical records. MAKE30 is defined as all-cause death, new RRT (any modality), or ≥25% decline in eGFR from baseline within 30 days post-surgery. eGFR is calculated using the CKD-EPI formula; baseline is defined as the most recent pre-operative value.

  6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels

    Time frame: Pre-surgery (baseline), postoperative day 1, day 3, and day 7 or at hospital discharge, whichever came first.

    Peripheral venous blood samples are collected and sent to the central laboratory for serum ALT and AST measurement using an automated biochemical analyzer. Normal reference ranges and assay methods follow each center's standard operating procedures.

  7. Blood cell counts, including white blood cell count (WBC), red blood cell count (RBC), and platelet count (PLT)

    Time frame: Postoperative day 1, day 3, and day 7 or at hospital discharge, whichever came first.

    Peripheral venous blood samples are collected and measured using an automated hematology analyzer

  8. Incidence of adverse events, including dysgeusia, rash, and gastrointestinal reactions (nausea, vomiting, diarrhea, abdominal pain, etc.)

    Time frame: From post-surgery to discharge (within 30-day follow-up period)

    Adverse events are recorded based on investigator inquiry and subject self-report, including event name, onset time, severity, duration, outcome, and causality with the study drug. Severity is graded according to CTCAE 5.0 criteria (Grade 1-5), and causality with the study drug is determined by the investigator

Other outcomes

  1. Cardiac troponin T (cTnT), creatine kinase-MB (CK-MB), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels

    Time frame: Pre-surgery (baseline), 24 hours post-surgery, 48 hours post-surgery, and 72 hours post-surgery

    Peripheral venous blood samples are collected; cTnT and NT-proBNP are measured by electrochemiluminescence immunoassay, and CK-MB by immunoinhibition assay

  2. Serum concentrations of IL-6, CRP, Cystatin C, MDA, TXB₂, and HSP70

    Time frame: At baseline (immediately before surgery), at 6 hours after the end of surgery, and at 24 hours after the end of surgery

  3. Urinary concentrations of NGAL and KIM-1 (renal tubular injury biomarkers)

    Time frame: Baseline (prior to surgery), 6 hours after surgery, 24 hours after surgery, and 48 hours after surgery

Study contacts

Contact information is provided by the study sponsor or research team.

Qiquan Sun, Professor

CONTACT

[email protected]

+86 13825109488

Sponsors and collaborators

Lead sponsor

Guangdong Provincial People's Hospital

Other

Registry information

Official study title

Terbinafine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury: A Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jul 31, 2026
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.